CHANGE IN KDIGO KIDNEY RISK CATEGORY WITH SEMAGLUTIDE TREATMENT-A POST HOC ANALYSIS OF THE SUSTAIN 6 TRIAL

被引：0
|
作者：
Tuttle, Katherine [1 ]
Bain, Stephen C. [2 ]
Cherney, David [3 ]
Lawson, Jack [4 ]
Rasmussen, Soren [4 ]
Vrhnjak, Blaz [4 ]
Khunti, Kamlesh [5 ]
机构：
[1] Univ WA Providence Hlth, Spokane, WA 99258 USA
[2] Swansea Univ, Med Sch, Swansea, W Glam, Wales
[3] Univ Toronto, Univ Hlth Network, Toronto, ON, Canada
[4] Novo Nordisk AS, Soborg, Denmark
[5] Univ Leicester, Leicester, Leics, England
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2022年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
MO462
引用
收藏
页码：I331 / I331
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of semaglutide in subjects with type 2 diabetes by race and ethnicity: a post hoc analysis of the SUSTAIN trials
    Desouza, C.
    Garg, S.
    Cariou, B.
    Furberg, J. K.
    Navarria, A.
    Nayak, G.
    Fonseca, V.
    DIABETOLOGIA, 2018, 61 : S369 - S370
  • [42] Efficacy of Semaglutide by Background Sodium-Glucose Cotransporter 2 Inhibitor: A Post Hoc Analysis of SUSTAIN 9
    Zinman, Bernard
    Bhosekar, Vaishali
    Busch, Robert S.
    Holst, Ingrid
    Ludvik, Bernhard
    Thrasher, James
    Woo, Vincent C.
    Philis-Tsimikas, Athena
    DIABETES, 2019, 68
  • [43] Semaglutide Reduces Mace Consistently Across Baseline Triglyceride Levels in Patients With Type 2 Diabetes: A Post Hoc Analysis of the Sustain 6 and Pioneer 6 Trials
    Verma, Subodh
    Leiter, Lawrence A.
    Michelsen, Marie M.
    Orsted, David
    Rasmussen, Soren
    Bhatt, Deepak L.
    CIRCULATION, 2020, 142
  • [44] Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Multinational Trial
    Levin, Adeera
    Perkovic, Vlado
    Wheeler, David C.
    Hantel, Stefan
    George, Jyothis T.
    von Eynatten, Maximilian
    Koitka-Weber, Audrey
    Wanner, Christoph
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2020, 15 (10): : 1433 - 1444
  • [45] Derived time in glycaemic range with once-weekly semaglutide vs active comparator: post hoc analysis from the SUSTAIN clinical trial programme
    Aroda, V. R.
    De Block, C.
    Kaltoft, M.
    Lawson, J.
    Sondergaard, A. L.
    Philis-Tsimikas, A.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 251 - 251
  • [46] Reduced glycaemic variability with once-weekly semaglutide vs active comparators in post hoc analysis of the SUSTAIN programme
    Jodar, E.
    Aroda, V. R.
    Kose, Y.
    Kaltoft, M.
    Sondergaard, A. L.
    Pratley, R.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 250 - 250
  • [47] Efficacy and safety of semaglutide by background sodium-glucose cotransporter-2 inhibitor: a post hoc analysis of SUSTAIN 9
    Ludvik, B.
    Bhosekar, V.
    Busch, R. S.
    Holst, I.
    Philis-Tsimikas, A.
    Thrasher, J.
    Woo, V. C.
    Yildirim, E.
    Zinman, B.
    DIABETOLOGIA, 2019, 62 : S375 - S375
  • [48] Semaglutide reduces the risk of major adverse cardiovascular events consistently across baseline triglyceride levels in patients with type 2 diabetes: Post hoc analyses of the SUSTAIN 6 and PIONEER 6 trials
    Verma, Subodh
    David, Jens-Peter
    Leiter, Lawrence A.
    Michelsen, Marie Mide
    Rasmussen, Soren
    Bhatt, Deepak L.
    DIABETES OBESITY & METABOLISM, 2023, 25 (08): : 2388 - 2392
  • [49] Machine Learning-Based Optimization of Patient Eligibility for Oral Insulin Treatment-A Post Hoc Analysis of Phase III Trial Results
    Kidron, Miriam
    Berkman, Elad
    Machluf, Oshri
    Pryluk, Raviv
    Homer, Kenneth E.
    Neutel, Joel M.
    DIABETES, 2024, 73
  • [50] Reduced Glycemic Variability with Once-Weekly Semaglutide vs. Active Comparators in Post-hoc Analysis of the SUSTAIN Program
    Pratley, Richard E.
    Aroda, Vanita R.
    Hindsberger, Charlotte
    Kose, Yasemin
    Kaltoft, Margit
    Jodar, Esteban
    DIABETES, 2021, 70
12345